FY2024 Earnings Estimate for MOLN Issued By Leerink Partnrs

Molecular Partners AG (NASDAQ:MOLN) – Stock analysts at Leerink Partnrs issued their FY2024 earnings estimates for Molecular Partners in a note issued to investors on Thursday, March 6th. Leerink Partnrs analyst J. Chang expects that the company will post earnings of ($1.93) per share for the year. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. Leerink Partnrs also issued estimates for Molecular Partners’ Q4 2024 earnings at ($0.45) EPS and FY2025 earnings at ($1.71) EPS.

Molecular Partners Stock Down 4.4 %

MOLN stock opened at $4.69 on Monday. The stock has a 50-day simple moving average of $5.10 and a two-hundred day simple moving average of $5.36. Molecular Partners has a twelve month low of $3.32 and a twelve month high of $12.70. The firm has a market capitalization of $189.10 million, a PE ratio of -2.18 and a beta of 1.06.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%.

Hedge Funds Weigh In On Molecular Partners

A hedge fund recently raised its stake in Molecular Partners stock. Suvretta Capital Management LLC raised its position in Molecular Partners AG (NASDAQ:MOLN) by 455.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,221,494 shares of the company’s stock after purchasing an additional 1,821,494 shares during the period. Suvretta Capital Management LLC owned 5.50% of Molecular Partners worth $10,548,000 at the end of the most recent reporting period. Institutional investors own 26.55% of the company’s stock.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.